000278928 001__ 278928
000278928 005__ 20250606100749.0
000278928 0247_ $$2doi$$a10.1016/B978-0-12-822240-9.00009-0
000278928 037__ $$aDZNE-2025-00654
000278928 041__ $$aEnglish
000278928 1001_ $$0P:(DE-2719)2812972$$aBerron, David$$b0$$eFirst author$$udzne
000278928 245__ $$aAdvances in cognitive testing
000278928 260__ $$bElsevier$$c2025
000278928 29510 $$aEarly Detection in Alzheimer' s Disease / Berron, David ; : Elsevier, 2025, ; ISBN: 9780128222409 ; doi:10.1016/B978-0-12-822240-9.00009-0
000278928 300__ $$a161 - 184
000278928 3367_ $$2ORCID$$aBOOK_CHAPTER
000278928 3367_ $$07$$2EndNote$$aBook Section
000278928 3367_ $$2DRIVER$$abookPart
000278928 3367_ $$2BibTeX$$aINBOOK
000278928 3367_ $$2DataCite$$aOutput Types/Book chapter
000278928 3367_ $$0PUB:(DE-HGF)7$$2PUB:(DE-HGF)$$aContribution to a book$$bcontb$$mcontb$$s1749125649_19817
000278928 520__ $$aRecent developments in Alzheimer's disease biomarkers have significantly improved the early detection of Alzheimer's disease pathology (Hansson et al., 2023; Ossenkoppele and Hansson, 2021; Zetterberg and Blennow, 2021) [1-3]. However, while biomarkers for Alzheimer's disease can indicate the underlying brain pathology and have some predictive value for future cognitive decline, they do not provide information about cognitive Alzheimer's disease phenotypes, particularly in early disease stages (Dubois et al., 2021) [4], nor do they represent optimal measures of disease progression. Thus, it is of critical importance to identify, characterize, and monitor cognitive impairment in Alzheimer's disease using cognitive assessments. While capturing subtle cognitive changes and impairment in early disease stages still remains challenging (Weintraub et al., 2018) [5], several new approaches have recently been utilized to improve the early detection of subtle cognitive impairment and decline. In this chapter, I will first provide an overview of novel cognitive test paradigms that are tailored toward cognitive functions of which the functional anatomy overlaps with spatial patterns of accumulation of Alzheimer's disease pathology; these paradigms aim to capture signs of early impairment with greater sensitivity than previous measures. I will then illustrate new approaches to cognitive testing that build on recent technological developments (Koo and Vizer, 2019; Kourtis et al., 2019) [6,7] and aim to assess cognitive performance even outside clinical settings.
000278928 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278928 588__ $$aDataset connected to CrossRef Book
000278928 773__ $$a10.1016/B978-0-12-822240-9.00009-0
000278928 8564_ $$uhttps://pub.dzne.de/record/278928/files/DZNE-2025-00654_Restricted.pdf
000278928 8564_ $$uhttps://pub.dzne.de/record/278928/files/DZNE-2025-00654_Restricted.pdf?subformat=pdfa$$xpdfa
000278928 909CO $$ooai:pub.dzne.de:278928$$pVDB
000278928 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812972$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000278928 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278928 9141_ $$y2025
000278928 9201_ $$0I:(DE-2719)5000070$$kAG Berron$$lClinical Cognitive Neuroscience$$x0
000278928 980__ $$acontb
000278928 980__ $$aVDB
000278928 980__ $$aI:(DE-2719)5000070
000278928 980__ $$aUNRESTRICTED